Open account
Sign up/Log in
MARKET
PHG
PHG
Koninklijke Phil
NYSE
19.98
0.00
0.00%
After Hours: 19.98 0 0.00% 16:00 04/19 EDT
OPEN
20.03
PREV CLOSE
19.98
HIGH
20.14
LOW
19.95
VOLUME
544.94K
TURNOVER
0
52 WEEK HIGH
24.27
52 WEEK LOW
17.74
MARKET CAP
18.11B
P/E (TTM)
-35.6404
1D
5D
1M
3M
1Y
5Y
Inspire Medical rebounds as J.P. Morgan defends after Lilly sleep data
Seeking Alpha · 2d ago
Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder
Seeking Alpha · 2d ago
Weekly Report: what happened at PHG last week (0408-0412)?
Weekly Report · 4d ago
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 5d ago
Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities
Seeking Alpha · 6d ago
UPDATE 1-Agnellis' Exor targets growth in healthcare sector
Agnellis' Exor targets growth in healthcare sector. Has already invested almost 4 billion euros in healthcare. Has cash firepower of 1.7 bln euros already allocated. To receive around 1.1 bln euro in dividends during 2024. Exor is the investment arm of the Agnelli family.
Reuters · 04/11 09:35
Exor has growing interest in healthcare industry
Exor has growing interest in the healthcare industry. The investment arm of the Agnelli family has already invested almost 4 billion euros in the industry. Exor views healthcare as a "long-term, structural growth sector" Exor's investments cover a broad range of industries.
Reuters · 04/11 08:43
Mizuho sees ResMed as "overwhelming beneficiary" of Philips consent decree
Mizuho sees ResMed as "overwhelming beneficiary" of Philips consent decree. ResMed is positioned to retain more than $450M in US market share gains for "much longer" than anticipated. Mizuho has a buy rating on ResMed with a price target of $215.
Seeking Alpha · 04/10 19:46
About PHG
Koninklijke Philips NV is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.
Webull offers Koninklijke Philips NV (ADR) stock information, including NYSE: PHG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading PHG stock methods without spending real money on the virtual paper trading platform.